Ovid Historical Financial Ratios
| OVID Stock | USD 0.41 0.02 4.65% |
Ovid Therapeutics is promptly reporting on over 106 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 3.28 will help investors to properly organize and evaluate Ovid Therapeutics financial condition quickly.
Ovid |
About Ovid Financial Ratios Analysis
Ovid TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Ovid Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Ovid financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Ovid Therapeutics history.
Ovid Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Ovid Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Ovid Therapeutics sales, a figure that is much harder to manipulate than other Ovid Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Most ratios from Ovid Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Ovid Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ovid Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.At present, Ovid Therapeutics' Stock Based Compensation To Revenue is projected to increase based on the last few years of reporting. The current year's EV To Sales is expected to grow to 102.78, whereas Book Value Per Share is forecasted to decline to 0.91.
| 2024 | 2025 (projected) | Days Sales Outstanding | 3.69 | 3.28 | PTB Ratio | 0.97 | 0.92 |
Ovid Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Ovid Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ovid Therapeutics fundamentals Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Ptb Ratio | 3.09 | 1.21 | 0.99 | 2.59 | 0.97 | 0.92 | |
| Book Value Per Share | 0.75 | 2.66 | 1.88 | 1.24 | 0.96 | 0.91 | |
| Free Cash Flow Yield | (0.38) | 0.55 | (0.43) | (0.2) | (0.85) | (0.8) | |
| Operating Cash Flow Per Share | (0.88) | 1.76 | (0.78) | (0.65) | (0.79) | (0.83) | |
| Capex To Depreciation | 1.27 | 0.8 | 1.03 | 0.0861 | 0.12 | 0.11 | |
| Pb Ratio | 3.09 | 1.21 | 0.99 | 2.59 | 0.97 | 0.92 | |
| Free Cash Flow Per Share | (0.89) | 1.75 | (0.8) | (0.65) | (0.79) | (0.83) | |
| Roic | (0.86) | (1.51) | 0.68 | (0.35) | (0.44) | (0.75) | |
| Net Income Per Share | (1.38) | 1.82 | (0.73) | (0.74) | (0.37) | (0.39) | |
| Cash Per Share | 1.23 | 2.78 | 3.03 | 1.5 | 0.75 | 0.71 | |
| Pocfratio | (2.62) | 1.83 | (2.37) | (4.96) | (1.18) | (1.24) | |
| Capex To Operating Cash Flow | (0.007574) | 0.001597 | (0.0257) | (0.003002) | (0.001269) | (0.001332) | |
| Pfcf Ratio | (2.6) | 1.83 | (2.31) | (4.95) | (1.18) | (1.24) | |
| Income Quality | 0.64 | 0.97 | 1.02 | 0.87 | 2.12 | 2.22 | |
| Roe | (0.85) | (1.85) | 0.68 | (0.39) | (0.6) | (0.41) | |
| Ev To Operating Cash Flow | (1.22) | 0.24 | (0.34) | (4.72) | (0.74) | (0.77) | |
| Pe Ratio | (1.67) | 1.76 | (2.55) | (4.34) | (2.5) | (2.63) | |
| Return On Tangible Assets | (1.07) | 0.63 | (0.33) | (0.36) | (0.29) | (0.3) | |
| Ev To Free Cash Flow | (1.21) | 0.24 | (0.33) | (4.71) | (0.74) | (0.77) | |
| Earnings Yield | (0.6) | 0.57 | (0.39) | (0.23) | (0.4) | (0.42) | |
| Intangibles To Total Assets | 0.004201 | 8.43E-4 | 0.00143 | 0.00127 | 0.001143 | 0.00208 | |
| Net Debt To E B I T D A | 0.89 | (1.51) | 2.13 | 0.19 | 0.4 | 0.38 | |
| Current Ratio | 3.39 | 12.87 | 18.79 | 9.55 | 5.32 | 5.05 | |
| Tangible Book Value Per Share | 0.74 | 2.66 | 1.88 | 1.24 | 0.96 | 0.91 | |
| Shareholders Equity Per Share | 0.75 | 2.66 | 1.88 | 1.24 | 0.96 | 0.91 | |
| Capex Per Share | 0.006684 | 0.002807 | 0.0201 | 0.001947 | 0.001001 | 9.51E-4 | |
| Graham Net Net | 0.68 | 2.56 | 2.7 | 0.7 | 0.41 | 0.39 | |
| Enterprise Value Over E B I T D A | (0.78) | 0.23 | (0.35) | (3.75) | (0.67) | (0.7) | |
| Price Earnings Ratio | (1.67) | 1.76 | (2.55) | (4.34) | (2.5) | (2.63) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ovid Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ovid Therapeutics. If investors know Ovid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ovid Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.37) | Revenue Per Share | Quarterly Revenue Growth (0.47) | Return On Assets | Return On Equity |
The market value of Ovid Therapeutics is measured differently than its book value, which is the value of Ovid that is recorded on the company's balance sheet. Investors also form their own opinion of Ovid Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Ovid Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ovid Therapeutics' market value can be influenced by many factors that don't directly affect Ovid Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ovid Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ovid Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ovid Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.